Biogen Idec and mondoBIOTECH AG have signed an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of Pulmonary Arterial Hypertension (PAH). Under terms of the agreement, mondoBIOTECH will receive a $7.5 million upfront payment and as much as $30 million in milestones for successful development and commercialization of Aviptadil in PAH in the U.S. and Europe, as well as royalty payments on c...